Belgium’s MRM Health Raises €55 Million In Series B Round

The round was led by French pharma group Biocodex, with participation from ATHOS, BNP Paribas Fortis Private Equity, and existing investors including SFPIM, AvH, OMX, Qbic II, and VIB.

"This funding marks a pivotal moment for MRM Health" said Sam Possemiers CEO of MRM Health. "With the support of our experienced international investor syndicate, we are now well positioned to deliver transformative therapies for patients with chronic inflammatory diseases where current treatments often fall short. Our CORAL platform gives us a unique edge in designing potent, resilient and scalable microbiome-based therapeutics. This new funding will allow us to further build both our platform and pipeline."

Read Also - Driven Raises €1.5M Funding To Transform Sales Commissions Management

Founded in 2020, MRM Health is a biopharmaceutical company specializing in therapeutics derived from the human microbiome. Based in a BioTech cluster Center of Expertise and partnered with VIB, the company develops live microbial therapies using its proprietary CORAL platform, which designs and manufactures disease-targeted microbial consortia with improved efficacy and scalability.

"Biocodex is a pioneer in microbiota science for over 70 years," said Nicolas Coudurier, CEO of Biocodex. "We are excited to support MRM Health’s unique platform approach and leadership role in the field, reflecting our strategy of fostering innovation rooted in our core expertise. By combining our long-standing leadership in microbiota with breakthrough live biotherapeutics platforms, we aim to deliver meaningful solutions for patients, worldwide."

The funds will allow MRM Health to complete a Phase 2b trial of its lead therapy, MH002, for patients with mild-to-moderate ulcerative colitis. MH002, a rationally designed microbial consortia, has shown safety and initial efficacy in Phase 2a trials for ulcerative colitis and pouchitis.

Additionally, MRM Health will advance two new microbial consortia programs toward IND approval, targeting inflammation and enhancing immune-oncology therapies. The company also aims to grow its LBP portfolio through strategic partnerships in both human and animal health.

"MRM Health is at the forefront of a new era in microbiome-based therapeutics," said Julian Zachmann, from ATHOS. "Their technology has reached the maturity needed to effectively develop, scale and commercialise live biotherapeutics for major chronic inflammatory diseases with high unmet need. We are proud to support their journey toward significant patient impact."

Under the financing agreement, MRM Health and Biocodex plan a strategic collaboration to develop new therapeutic assets and scalable manufacturing for LBPs. The partnership will also provide additional non-dilutive funding over the coming years further reinforcing MRM Health’s operational capabilities.

"BNP Paribas Fortis Private Equity is delighted to join a strong syndicate of investors to support the further development of MRM Health. With two decades of unique scientific expertise in the field of microbiome, this funding round reflects our confidence in MRM Health’s technology and the management’s ability to translate science into therapeutic solutions that will truly make a difference for patients," said Raf Moons, Head of BNP Paribas Fortis Private Equity.

Following the Series B financing, Jean-Patrick Hennebelle (Biocodex), Julian Zachmann (ATHOS), and Goedele Ertveldt (SFPIM) will join MRM Health’s Board of Directors.

"We warmly welcome our new investors and thank them for their trust," said Werner Cautreels, Chairman of MRM Health Board of Directors. "With this strong international syndicate, MRM Health is well equipped to advance its pipeline and deliver this novel class of therapeutics to patients in need of alternative, innovative treatment options."

About MRM Health

MRM Health NV, based in Ghent, Belgium, develops innovative microbiome-based therapeutics. Partnering with VIB and supported by top investors, the company uses a proprietary platform to create optimized microbial consortia, advancing live biotherapeutic development for metabolic, inflammatory, and immune-related diseases with enhanced efficacy and scalability.